Loading data for APMD — first visit, this takes a few seconds.
Apnimed Inc. (APMD)
NasdaqGS: APMD
· Real-Time Price · USD
28.03
-0.52 (-1.82%)
At close: Aug 21, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Apnimed Inc. (APMD) Stock Price, Analysis & Data
-1.82% (1D)
No data available
| Bid | 31.14 |
| Market Cap | 1.12B |
| Revenue (ttm) | 120.15M |
| Net Income (ttm) | 39M |
| n/a | |
| 3.46 | |
| 8.1 | |
| n/a | |
| P/B (ttm) | -0.52 |
| P/S (ttm) | 9.29 |
| Earnings Date | n/a |
| Ask | 32.26 |
| Volume | 246,332 |
| Avg. Volume (20D) | 581,043 |
| Open | 29.34 |
| Previous Close | 28.55 |
| Day's Range | 27.64 - 29.56 |
| 52-Week Range | 16.12 - 35.29 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About APMD
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2026
Employees 65
Stock Exchange NasdaqGS
Ticker Symbol APMD
Website https://apnimed.com
Financial Performance
In 2025, Apnimed's revenue was 38.47M, an increase of 380.12% compared to the previous year's 8.01M. Earnings were -932K, a decrease of -99.16%.
Financial Statements
